Unveiling a Potential Breakthrough: Prostate Cancer Drugs Targeting Leukemia
A groundbreaking study has revealed a promising connection between drugs designed to treat prostate cancer and their potential effectiveness against acute myeloid leukemia (AML). Researchers at Penn State have discovered that apalutamide and finasteride, both FDA-approved for prostate cancer treatment, exhibit remarkable efficacy in combating AML in experimental models and patient-derived cells.
The study, published in the journal Blood Advances, sheds light on the androgen receptor's role in AML. K. Sandeep Prabhu, a lead author, explains that these drugs inhibit the pathway activated by dihydrotestosterone, an androgen hormone more potent than testosterone. This discovery challenges the conventional understanding of AML treatment, as androgen signaling has been primarily studied in prostate cancer.
Robert Paulson, a co-author, emphasizes the significance of this finding, stating that AML is a challenging disease with limited treatment options. The identification of the androgen receptor as a new target, coupled with the availability of FDA-approved drugs, offers a glimmer of hope. The next steps involve clinical trials to assess the drugs' effectiveness in patients.
The study's origin can be traced back to Fenghua Qian's work on developing an AML mouse model. During this process, Qian observed that female mice had a lower chance of developing AML, while male mice exhibited an unusually aggressive form of the disease. This led him to explore the role of androgen receptors, which are highly expressed in female donor leukemic cells. Interestingly, even in the absence of estrogen, female mice still had a reduced risk of AML, suggesting a different protective mechanism.
The researchers made a crucial discovery: high dihydrotestosterone levels in male mice promoted AML development despite low androgen receptors in their leukemia cells. Conversely, female mice with low dihydrotestosterone levels had high androgen receptors in their leukemia cells, indicating a potential target for treatment. This finding was consistent across both mouse models and human patient transplants.
Finasteride and apalutamide demonstrated their effectiveness by inhibiting dihydrotestosterone and targeting different pathways in androgen receptor activity, respectively. This study introduces a novel approach to leukemia treatment, as androgen receptors have never been considered a target before.
Fenghua Qian, a senior scientist at Regeneron, highlights the potential benefits of this discovery. By targeting androgen receptors and their interactors, the treatment could be effective for patients resistant to traditional therapies. However, he emphasizes the need for further testing, including clinical trials with strict inclusion criteria, to ensure the safety and efficacy of these drugs in leukemia patients.
The study's success is attributed to Fenghua Qian's vigilance and attention to detail, which led to the identification of a new treatment avenue. This research not only opens up exciting possibilities for AML treatment but also underscores the importance of meticulous observation in scientific discovery.
